Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASGR1 | P07306 | 10/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18722938 | 0.90 | ASGR1 (0.65) | ASGR1SMN1; SMN2MAPK1 | |
| SCHEMBL18722868 | 0.89 | ASGR1 (0.67) | ASGR1MAPK1 | |
| SCHEMBL18722900 | 0.87 | ASGR1 (0.69) | ASGR1MAPK1 | |
| SCHEMBL18722865 | 0.85 | ASGR1 (0.53) | ASGR1 | |
| SCHEMBL22021917 | 0.83 | ASGR1 (0.53) | ASGR1 | |
| SCHEMBL18722934 | 0.83 | ASGR1 (0.59) | ASGR1ALDH1A1THRB | |
| SCHEMBL21249100 | 0.82 | ASGR1 (0.51) | ASGR1 | |
| SCHEMBL18967925 | 0.82 | ASGR1 (0.51) | ASGR1 | |
| SCHEMBL18722866 | 0.81 | ASGR1 (0.47) | ASGR1 | |
| SCHEMBL17256414 | 0.78 | ASGR1 (1.00) | ASGR1MAPK1ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | PFIZER INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10376531-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10039778-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170165284-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | PFIZER INC. (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170137801-A1 | TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-05-18 | — | — | US | disclosed |
| US-9617293-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | PFIZER INC. (US) | 2017-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165284-A1 | SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR | ASGR1, MRGPRX2, LDLR | ASGR1 1/4885SMN1; SMN2 3913/4885MAPK1 2241/4885 |
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | ASGR1, LDLR, HAVCR2 | ASGR1 1/4885SMN1; SMN2 2411/4885MAPK1 3145/4885 |
| US-10039778-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | ASGR1, MRGPRX2, LDLR | ASGR1 1/4885SMN1; SMN2 3913/4885MAPK1 2241/4885 |
| US-10376531-B2 | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR | ASGR1, MRGPRX2, LDLR | ASGR1 1/4885SMN1; SMN2 3913/4885MAPK1 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.